WO2016062274A1 - 消化系统疾病用药物在制备抑制癌症的医药组合物中的应用 - Google Patents

消化系统疾病用药物在制备抑制癌症的医药组合物中的应用 Download PDF

Info

Publication number
WO2016062274A1
WO2016062274A1 PCT/CN2015/092702 CN2015092702W WO2016062274A1 WO 2016062274 A1 WO2016062274 A1 WO 2016062274A1 CN 2015092702 W CN2015092702 W CN 2015092702W WO 2016062274 A1 WO2016062274 A1 WO 2016062274A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
drug
use according
agent
digestive
Prior art date
Application number
PCT/CN2015/092702
Other languages
English (en)
French (fr)
Inventor
陈丘泓
庄秀美
萧乃文
梁瑞岳
陈筱彤
Original Assignee
朗齐生物医学股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朗齐生物医学股份有限公司 filed Critical 朗齐生物医学股份有限公司
Publication of WO2016062274A1 publication Critical patent/WO2016062274A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to the application of new indications for a variety of digestive system diseases, in particular to the use of the plurality of drugs for clinical trials and for inhibiting various cancers.
  • Cancer has long been the leading cause of death worldwide, and the number of cancer patients has increased year by year. Therefore, treating cancer has become an important issue.
  • the treatment of cancer can be divided into surgical treatment, radiation therapy, chemotherapy and target treatment.
  • cancer drug treatment is intended to prevent cancer cells from replicating and dividing to block the spread and spread of tumors.
  • chemotherapy chemotherapy or target treatment
  • cancer drug treatment is intended to prevent cancer cells from replicating and dividing to block the spread and spread of tumors.
  • chemotherapeutic drugs and target treatment hoping to kill cancer cells by different mechanisms to improve the therapeutic effect, but in fact, patients often react to the treatment of drugs Not good.
  • many cancer cells successively develop drug resistance, which greatly reduces the effectiveness of drug use, and ultimately leads to failure of cancer treatment.
  • the digestive system is a group of organs used by multicellular organisms to eat, digest food, gain energy and nutrients, and excrete residual waste. Its main functions are ingestion, digestion, absorption, assimilation and excretion. The part of the excretion can also be classified as part of the excretory system. Knee, diarrhea, lactose intolerance, constipation, snoring, heartburn, food poisoning, vomiting, nausea, flatulence, gastrointestinal ulcers, gallstones, hepatitis B, hepatitis C, gastroesophageal reflux, digestive ulcers, large intestine diverticulosis These are all diseases of the digestive tract.
  • the present invention mainly aims at the development of new indications for various drugs through clinical experiments, and achieves the goal of new use of old drugs.
  • the experimental design results show that the digestive system disease has no or only minimal toxicity to normal cells, but whether the digestive system disease has a selective effect between normal cells and tumor cells remains to be determined by more research. Not all digestive diseases are effective in inhibiting tumor cells under the same conditions, and many problems need to be overcome.
  • Digestive system diseases can be divided into many types according to the structure of the drug, including antiemetics, antidiarrheal agents, intestinal remedies, antispasmodic agents, antidiarrheal agents, other digestive system drugs, antacids, antacid anti-swelling agents , Respiratory stimulants, peptic ulcer therapeutic agents, gastric digestive agents, choleretic agents, emetic agents, antiemetic agents, laxatives, and other types.
  • Dicloneine and Dioscorea are two antispasmodic agents with anticholinergic action. These two drugs have general side effects and may worsen gastroesophageal reflux disease.
  • the antacid English name Antacids, contains aluminum or (and) magnesium compounds, mainly using the ability to neutralize gastric acid, to alleviate or prevent heartburn, bloating or indigestion caused by hyperacidity. Symptoms can also be used to treat or prevent ulcers.
  • the common antacid is a compound containing aluminum or (and) magnesium, which mainly utilizes the ability to neutralize gastric acid to alleviate or prevent heartburn, bloating or indigestion caused by hyperacidity. Symptoms can also be used to treat or prevent ulcers.
  • the main pharmacological effects of antacids are: alleviating or preventing symptoms of heartburn, bloating or indigestion caused by hyperacidity, and can also be used to treat or prevent ulcers, or to neutralize gastric acid.
  • respiratory excitement is a central stimulant, mainly through direct stimulation of the medullary respiratory center, but also by stimulating the carotid body and the chemoreceptor reflexive respiratory center of the aortic body, so that the deepening of the breathing is accelerated, the ventilation is increased, and the ventilation is increased.
  • the partial pressure of oxygen in the blood reduces the partial pressure of carbon dioxide in the blood. Improve the sensitivity of the respiratory center to carbon dioxide, especially when the respiratory center is in a state of inhibition.
  • attack factors include: (1) stomach acid and protein, (2) drugs, (3) alcohol, (4) smoking, (5) bile reflux, (6) bacteria such as Helicobacter pylori; and defensive factors including :1 Mucosal mucus and bicarbonate ion secretion, 2. surface cell barrier, 3. mucosal cell renewal, 4. mucosal blood flow supply, 5. endogenous prostate synthesis.
  • the attack factor also directly or indirectly affects the defensive factor, and is classified according to the site of occurrence, including (1) duodenal ulcer and (2) gastric ulcer.
  • gastric ulcer The age of gastric ulcer is about 10-20 years older than duodenal ulcer. It is more common in the age of 60-70 years. The incidence rate of male and female is slightly the same. It is the cause of duodenal ulcer relative to excessive gastric acid secretion.
  • gastric acid secretion in patients with gastric ulcer is mostly normal or less, while gastrin is in a high state, the gastric emptying speed is slow, and the gastric mucosa presents different degrees of chronic gastritis and gastric mucosal atrophy. .
  • the positive rate of Helicobacter pylori in patients with gastric ulcer is about 65-80%, higher than the average person, but lower than twelve.
  • the positive rate of patients with intestinal ulcer is relatively low, and the current treatment is still recommended for the clearance of Helicobacter pylori.
  • the above abdominal pain is the most common, but it is less typical than the pain of duodenal ulcer. If there is gastric bleeding or perforation, the chance of causing mortality is also higher than that of duodenal ulcer. high. Endoscopy is used for the diagnosis of patients with gastric ulcer.
  • tissue biopsy In addition to directly observing the changes in the size, shape, location and chronic inflammation of the ulcer, it can also be used for tissue biopsy to determine benign or malignant ulcers and to check for the presence of Helicobacter pylori. Whether or not.
  • the treatment like duodenal ulcers, including individuals and families suffering from malignant tumors, it is recommended that patients avoid using foods and drugs that aggravate ulcers; such as tobacco, alcohol and painkillers (NSAID), etc. Drug-based, and drugs associated with duodenal ulcer, but it seems that the healing of gastric ulcer is slower than duodenal ulcer, and larger ulcers also take longer to heal, positive for Helicobacter pylori test As a result, clearance of H. pylori is still recommended.
  • a medicament for digestive diseases is used in the preparation of a pharmaceutical composition for inhibiting cancer, wherein the pharmaceutical composition is an effective dose concentration of a digestive disease drug and a pharmaceutically acceptable salt.
  • the digestive disease drug is selected from the group consisting of an antiemetic agent, an antidiarrheal agent, an intestinal remedy agent, an antispasmodic agent, an antidiarrheal agent, other digestive system drugs, an antacid agent, and an antacid agent.
  • the anti-caries agent is a drug consisting of one or more of Moxonidine, Moexipril HCl, Alverine Citrate and Camylofin Chlorhydrate.
  • the antacid is Esomeprazole magnesium (Nexium) or / and Roxatidine acetate HCl.
  • the respiratory stimulant is a Sorbitol (Glucitol) drug.
  • the therapeutic agent for gastric ulcer is Danofloxacin Mesylate and/or Bentiromide.
  • the acute abdominal pain drug is a Rofecoxib drug.
  • the cancer is one or more selected from the group consisting of lung cancer, intestinal cancer, colorectal cancer, prostate cancer, liver cancer, bladder cancer, cervical cancer, breast cancer, and kidney cancer.
  • the effective dose concentration of the drug is from 20 mg/kg to 500 mg/kg per day.
  • Fig. 1 shows the results of analysis of cancer cells used in the digestive system of the present invention.
  • the cell lines of different cancer types were subcultured, and after counting the number of cells, 2 ⁇ 10 6 cells were placed in a Petri dish, and then the culture medium in which the cell strain was cultured was added to a volume of 10 ml, and continued. Train for 2-3 days. The cells were then counted and dispensed into 96-well plates where the number of cells per well was fixed at 3000 cells and the volume was 100 ul.
  • IC50 is the semi-inhibitory concentration (or semi-inhibition rate). It is a very important data in the indirect competition ELISA standard curve, and the standard curve is an S-shaped curve.
  • the OD value of the control group without drug addition was B0
  • the OD value of the experimental group to which the drug was added was B
  • B/B0% was called the binding rate
  • the concentration of the drug at the binding rate was 50%. It is called IC50.
  • the smaller the value of IC50 the stronger the inhibitory effect of the drug.
  • the original culture solution in the 96-well plate was aspirated, and a commercially available drug having a concentration of 10 ⁇ M and a volume of 100 ul was added to each well. After 72 hours, 100 ul of diluted WST-1 reagent was added to each well, and the dilution ratio was the culture solution and The volume ratio of WST-1 stock solution is 9:1. Finally, the total volume of each well plate is 200ul. Then, the 96-well plate is placed at 37 °C for 30-90 minutes. ELISA reader (ELISA) is used for OD450. The absorbance values were detected and the survival rate of each cancer cell line was calculated.
  • ELISA reader ELISA reader
  • Digestive system disease is used to inhibit cancer cell analysis results
  • Digestive system diseases are divided into several categories, respectively, digestive diseases are selected from antiemetics, antidiarrheal agents, intestinal remedies, antispasmodics, antidiarrheal agents, other digestive system drugs, antacids, antacids Inhibition of cancer cells by swelling agent, respiratory stimulant, peptic ulcer therapeutic agent, stomach digestive agent choleretic agent, emetic agent, antiemetic agent, sedative agent, and one or more digestive system diseases .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

消化系统疾病用药物在制备抑制癌症的医药组合物中的应用，所述消化系统疾病用药物为抗痉挛剂、抗腹泻剂、制酸剂、呼吸兴奋剂、胃溃疡治疗剂、急性腹痛治疗剂中的一种或多种。

Description

消化系统疾病用药物在制备抑制癌症的医药组合物中的应用 技术领域
本发明涉及多种消化系统疾病用药的新适应症的应用，特别涉及该多种药物为通过临床实验且具有抑制多种癌症的用途。
背景技术
癌症长期高居全球死因之首，且罹患癌症人数更是逐年攀升，因此治疗癌症俨然成为重要的课题。癌症的治疗可区分为手术治疗、放射线治疗、化学治疗及标靶治疗。
一般来说，癌症药物治疗无论是化学治疗或标靶治疗，目的多是让癌细胞无法复制、分裂，来阻断肿瘤的蔓延扩张。在临床治疗选择上，通常会结合一到数种化疗药物以及标靶治疗，希望能藉由不同机制来杀死癌细胞以提高治疗效果，但事实上，还是常遇到患者对于治疗药物的反应不佳。进一步，许多癌细胞相继产生抗药性，使药物的使用成效大幅降低，最终导致癌症治疗失败。
消化系统是多细胞生物用以进食、消化食物、获取能量和营养、排泄剩余废物的一组器官，其主要功能为摄取、消化、吸收、同化和排泄。其中有关排泄的部分，也可归类到排泄系统的一部分。下痢、腹泻、乳糖不耐症、便秘、打嗝、胃灼热、食物中毒、呕吐、恶心、胀气、肠胃溃疡、胆结石、B型肝炎、C型肝炎、胃食道逆流、消化行溃疡、大肠憩室症等皆属于消化道疾病。
发明人依据长年的研究经验，人类的癌症细胞常常有与正常细胞具有不同的表现性状，型态上的差异或是作用机转的变化或许也有可能被视为一种外来的 侵入者，而每一种癌症细胞所在的位置不同，变异的状态又与所处的环境有关，因此，第一个提出使用消化系统疾病用药抑制癌症细胞的发明概念并且进行实验。
相对的，在这些已经使用数十年消化系统疾病用药，是早已被FDA所认可的用药，具有大量药物机转及人体研究成果数据，因此，若应用在癌症方面，这项新发展会更省时、减少成本，也能和其他治疗方式结合来提高效果。目前尚未有任何研究针对本发明所使用之药物，进行癌症治疗研究。
尽管如此，药物开发依然是重要的医学议题，必须经过繁复的临床前试验才能进入临床试验，根据统计，平均每一万个新药约只有五个能够进入第一期临床试验。此外，除了药物本身是否能大量制造的难题外，还需克服药物安全性、病人筛选、试用剂量等问题，即便药物已经通过FDA的核准并上市，亦有可能因上市后于人体发现不良反应而强制下架回收，由此可见药物开发具有一定的困难程度。
发明内容
为解决上述的问题，本发明主要针对通过临床实验的多种药物进行新适应症的研发，而达到老药新用的目标。
经过实验设计结果显示消化系统疾病用药对正常细胞没有或仅有微小的毒性，但至于消化系统疾病用药在正常细胞与肿瘤细胞之间是否具有选择性的影响，还待更多的研究厘清，而且并非所有的消化系统疾病用药在相同的条件下均能有效的抑制肿瘤细胞，需要有许多的问题进行克服。
名词定义
消化系统疾病用药依据药物的结构可以分为許多类，包含止吐剂、止泻剂整肠剂、抗痉挛剂、抗腹泻剂、其他消化系统用药、制酸剂、制酸剂抗发胀剂、 呼吸兴奋剂、消化性溃疡治疗剂、健胃消化剂利胆剂、催吐剂镇吐剂镇晕剂、泻剂与其他类。
抗痉挛剂，用于平滑肌收缩，尤其是在胃肠道的管状器官。其效果是防止胃、肠或膀胱的痉挛。双环锥林(Dicycloverine)、及天仙子胺这两种是具有抗胆碱剂作用的解痉药。这两种药物具有一般的副作用，并且可能恶化胃食管反流病出。
制酸剂，英文名Antacids，内含铝或(及)镁之化合物为主，主要利用其中和胃酸的能力，用以缓解或预防因为胃酸过多所引起的心口灼热感、胃胀气或消化不良的症状，也可用来治疗或预防溃疡的发生。制酸剂常见的药物为内含铝或(及)镁之化合物为主，主要利用其中和胃酸的能力，用以缓解或预防因为胃酸过多所引起的心口灼热感、胃胀气或消化不良的症状，也可用来治疗或预防溃疡的发生。制酸剂的主要药理功效为：缓解或预防因为胃酸过多所引起的心口灼热感、胃胀气或消化不良的症状，也可用来治疗或预防溃疡的发生，或中和胃酸。
呼吸兴奋用药，呼吸兴奋属于中枢兴奋药，主要通过直接兴奋延髓呼吸中枢，也可通过刺激颈动脉体和主动脉体的化学感受器反射性的兴奋呼吸中枢，使呼吸加深加快，通气量增加，提高了血中氧分压，降低了血中二氧化碳分压。提高呼吸中枢对二氧化碳的敏感性，在呼吸中枢处于抑制状态时兴奋作用尤为明显。
消化性溃疡是指一群由胃酸或蛋白畊等攻击因子所造成上消化道形成溃疡性变化的疾病总称。目前学者们大多支持重要假说，就是攻击因子与胃肠黏膜的防御因子失衡所致。广义而言，攻击因子包括：(1)胃酸及蛋白，(2)药物，(3)酒精，(4)抽烟，(5)胆汁逆流，(6)细菌，如幽门螺旋杆菌；防御因子则包括：1 黏膜表面黏液及碳酸氢离子的分泌，2.表面细胞的屏障，3.黏膜细胞的更新，4.黏膜层血流的供应，5.内因性前列腺的合成。其中攻击因子亦会直接或间接影响防御因子，而依发生的部位来分类，主要包括(1)十二指肠溃疡和(2)胃溃疡。
胃溃疡好发年纪约比十二指肠溃疡多出10-20岁，以60-70岁的年龄较常见，男女发生比率略同，相对于胃酸分泌过多为十二指肠溃疡的致病主因，胃溃疡患者的胃酸分泌大多数为正常或较少，而胃泌素则呈偏高的状态，胃的排空速度较慢，且胃黏膜呈现不同程度的慢性胃炎及胃黏膜萎缩的现象。大多数学者都同意胃溃疡的发生原因为多因性，偏重于一些黏膜防卫机转的缺陷，至于幽门螺旋杆菌在胃溃疡患者阳性率约65-80％，高于一般人，但低于十二指肠溃疡患者的阳性率，相关性较低，目前治疗方面仍建议作幽门螺旋杆菌的清除。临床症状方面，以上腹痛最为常见，但相较于十二指肠溃疡的痛，则较不典型，若出现胃出血或穿孔的情况，其引起死亡率的机会，亦较十二指肠溃疡为高。内视镜用于胃溃疡患者的诊断，除了可直接观查溃疡之大小、形状、部位及慢性炎症的变化，亦可作组织切片生检，确定良性或恶性溃疡，及检查幽门螺旋杆菌的存在与否。至于治疗方面，如同十二指肠溃疡，包括个人及家族罹患恶性肿瘤的情形，建议病人避免使用加重溃疡的食物及药物；如烟、酒及止痛药(NSAID)等，胃溃疡治疗仍以内科药物为主，与十二指肠溃疡的药物相通，但似乎胃溃疡的愈合较十二指肠溃疡为慢，且较大的溃疡也须花费较长的时间愈合，呈阳性的幽门螺旋杆菌检验结果，仍建议作幽门螺旋杆菌的清除。
一种消化系统疾病用药物在制备抑制癌症的医药组合物中应用，其中所述医药组合物为有效剂量浓度的消化疾病药物和药学上可接受的盐类组成。
本发明一实施例中，其中所述消化疾病药物是选自止吐剂、止泻剂整肠剂、抗痉挛剂、抗腹泻剂、其他消化系统用药、制酸剂、制酸剂抗发胀剂、呼吸兴 奋剂、消化性溃疡治疗剂、健胃消化剂利胆剂、催吐剂镇吐剂镇晕剂、泻剂中的一种或多种消化系统疾病药物。
本发明一实施例中，其中所抗痉挛剂为Moxonidine、Moexipril HCl、Alverine Citrate及Camylofin Chlorhydrate中的一种或多种所组成的药物。
本发明一实施例中，其中所述制酸剂为Esomeprazole magnesium(Nexium)或/和Roxatidine acetate HCl。
本发明一实施例中，其中呼吸兴奋剂是Sorbitol(Glucitol)药物。
本发明一实施例中，其中所述胃溃疡治疗剂为Danofloxacin Mesylate和/或Bentiromide。
本发明一实施例中，其中所述急性腹痛药物为Rofecoxib药物。
本发明一实施例中，其中所述癌症是选自肺癌、肠道癌、大肠直肠癌、前列腺癌、肝癌、膀胱癌、子宫颈癌、乳癌、肾脏癌中的一种或多种。
本发明一实施例中，其中所述药物的有效剂量浓度为每日20mg/kg～500mg/kg。
现今癌症药物费用动辄上万至数百万元，若未来更进一步证实消化系统疾病用药对肿瘤的疗效，对于无法负担昂贵治疗的患者们，这些便宜而历史悠久的药物，会是带来健康的新希望。
附图说明
图1为本发明消化系统疾病用药应用于抑制癌细胞分析结果。
实施方式
建立细胞株
参照表一，将不同癌症类型的细胞株进行继代培养，计算细胞数目后，将2 ×106细胞数置入培养皿中，然后加入培养该细胞株的培养液补至体积为10ml，继续培养2-3天。之后将细胞计数，并分装至96孔盘，其中每孔的细胞数目固定为3000个细胞，且体积为100ul。
IC50即半抑制浓度(或称半抑制率)。在间接竞争ELISA标准曲线中是一个非常重要的数据，标准曲线是一个S型曲线。ICELISA中，不添加药物的对照组的OD值定为B0，添加了药物的实验组的OD值为B，B/B0％就叫做结合率，在结合率为50％时所对应的药物的浓度就叫做IC50。一般IC50的数值越小表示药物的抑制效果越强。
表一、细胞株及其培养所用的培养液
Figure PCTCN2015092702-appb-000001
Figure PCTCN2015092702-appb-000002
细胞存活分析方法
将96孔盘中原有的培养液吸掉，每孔加入浓度10μM、体积100ul的市售药物，放置72小时后，每孔再加入100ul已稀释的WST-1试剂，该稀释比例为培养液与WST-1原液的体积比为9：1，最后每个孔盘的总体积为200ul，然后将96孔盘放置于37℃，30～90分钟，利用ELISA reader(酶联免疫检测仪)于OD450侦测吸光值，并计算各癌症细胞株的存活率。
消化系统疾病用药应用于抑制癌细胞分析结果
消化系统疾病用药分为多类，分别为消化疾病药物是选自止吐剂、止泻剂整肠剂、抗痉挛剂、抗腹泻剂、其他消化系统用药、制酸剂、制酸剂抗发胀剂、呼吸兴奋剂、消化性溃疡治疗剂、健胃消化剂利胆剂、催吐剂镇吐剂镇晕剂、泻剂中的一种或多种消化系统疾病药物类抑制癌细胞生长的效果。
实验结果明显的显示有许多的消化系统疾病用药并无法有效的抑制癌症的细胞的生长，如表二。
表二、对癌症细胞株无抑制效果的消化系统疾病用药
消化道疾病药物 抑制癌症胞株数量
Ondansetron(Zofran) 0
Mizolastine(Mizollen) 0
而相对的各种的消化系统疾病用药分子对于各种癌症细胞的抑制效果也不尽相同(图一)，经过发明人实验结果，证实消化系统疾病用药药物Esomeprazole magnesium(Nexium)(埃索美拉唑镁(耐信))、Roxatidine acetate HCl(盐酸罗沙 替丁醋酸酯)、Moxonidine(莫索尼定)、Moexipril HCl(盐酸莫西普利)、Sorbitol(Glucitol)(山梨糖醇(葡萄糖醇))、Rofecoxib(Vioxx)(罗非昔布)、Alverine Citrate(枸橼酸阿尔维林)、Danofloxacin Mesylate(甲磺酸达氟沙星)、Troxipide(曲昔派特)、Bentiromide(苯替酪胺)、Camylofin Chlorhydrate(胺苯戊酯盐酸盐)等药物对于不同的癌症细胞有明显的抑制效果。实验结果如表三。
重复性实验
依据表三所示结果，针对对癌症细胞株有效的药物进行重复性实验，其结果如表四、五所示。
上列详细说明的针对本发明之一可行实施例的具体说明，惟该实施例并非用以限制本发明的专利范围，凡未脱离本发明技艺精神所为的等效实施或变更，均应包含于本发明的专利范围中。
Figure PCTCN2015092702-appb-000003
Figure PCTCN2015092702-appb-000004

Claims (9)

  1. 消化系统疾病用药物在制备抑制癌症的医药组合物中的应用，其特征是，所述医药组合物为有效剂量浓度的消化疾病药物及药学上可接受的盐类所組成。
  2. 如权利要求1所述的应用，其特征是，所述消化疾病药物为抗痉挛剂、抗腹泻剂、制酸剂、呼吸兴奋剂、胃溃疡治疗剂、急性腹痛治疗剂中的一种或多种。
  3. 如权利要求2所述的应用，其特征是，所述抗痉挛剂為Moxonidine、Moexipril HCl、Alverine Citrate及Camylofin Chlorhydrate中的一种或多种所组成的药物。
  4. 如权利要求2所述的应用，其特征是，所述制酸剂为Esomeprazole magnesium(Nexium)或/和Roxatidine acetate HCl。
  5. 如权利要求2所述的应用，其特征是，所述呼吸兴奋剂是Sorbitol(Glucitol)药物。
  6. 如申请专利范围第2项所述之应用，所述胃溃疡治疗剂为Danofloxacin Mesylate和/或Bentiromide。
  7. 如权利要求2所述的应用，其特征是，所述胃溃疡用药为Troxipide药物。
  8. 如权利要求2所述的应用，其特征是，所述急性腹痛药物为Rofecoxib药物。
  9. 如权利要求1所述的应用，其特征是，所述癌症是选自由肺癌、肠道癌、大肠直肠癌、前列腺癌、肝癌、膀胱癌、子宫颈癌、乳癌、血癌中的一种或多种。
PCT/CN2015/092702 2014-10-24 2015-10-23 消化系统疾病用药物在制备抑制癌症的医药组合物中的应用 WO2016062274A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24
US62/068,298 2014-10-24

Publications (1)

Publication Number Publication Date
WO2016062274A1 true WO2016062274A1 (zh) 2016-04-28

Family

ID=55760314

Family Applications (21)

Application Number Title Priority Date Filing Date
PCT/CN2015/092771 WO2016062283A1 (zh) 2014-10-24 2015-10-23 抗发炎用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092781 WO2016062290A1 (zh) 2014-10-24 2015-10-23 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092777 WO2016062287A1 (zh) 2014-10-24 2015-10-23 山喜多药物在用于制备抑制癌症的医药组合物中的用途
PCT/CN2015/092782 WO2016062291A1 (zh) 2014-10-24 2015-10-23 千忧解药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092677 WO2016062270A1 (zh) 2014-10-24 2015-10-23 呼吸系统疾病用药用于制备抗癌医药组合物的用途
PCT/CN2015/092775 WO2016062285A1 (zh) 2014-10-24 2015-10-23 神经系统疾病用药在制备抗癌医药组合物中的应用
PCT/CN2015/092768 WO2016062281A1 (zh) 2014-10-24 2015-10-23 心血管疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092653 WO2016062267A1 (zh) 2014-10-24 2015-10-23 奈必洛尔在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092666 WO2016062269A1 (zh) 2014-10-24 2015-10-23 阿那格雷在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092714 WO2016062275A1 (zh) 2014-10-24 2015-10-23 阿折地平在制备治疗癌症的医药组合物中的用途
PCT/CN2015/092761 WO2016062279A1 (zh) 2014-10-24 2015-10-23 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
PCT/CN2015/092779 WO2016062288A1 (zh) 2014-10-24 2015-10-23 代谢性疾病药物用于制备抑制癌症的医药组合物的用途
PCT/CN2015/092617 WO2016062265A1 (zh) 2014-10-24 2015-10-23 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092702 WO2016062274A1 (zh) 2014-10-24 2015-10-23 消化系统疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092697 WO2016062272A1 (zh) 2014-10-24 2015-10-23 免疫疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092776 WO2016062286A1 (zh) 2014-10-24 2015-10-23 脱克钙药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092753 WO2016062278A1 (zh) 2014-10-24 2015-10-23 内分泌疾病用药在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092780 WO2016062289A1 (zh) 2014-10-24 2015-10-23 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092632 WO2016062266A1 (zh) 2014-10-24 2015-10-23 氨氯地平在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092686 WO2016062271A1 (zh) 2014-10-24 2015-10-23 抗生素药物用于制备治疗癌症的医药组合物的用途
PCT/CN2015/092746 WO2016062277A1 (zh) 2014-10-24 2015-10-23 驱虫药用于制备抗癌医药组合物中的应用

Family Applications Before (13)

Application Number Title Priority Date Filing Date
PCT/CN2015/092771 WO2016062283A1 (zh) 2014-10-24 2015-10-23 抗发炎用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092781 WO2016062290A1 (zh) 2014-10-24 2015-10-23 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092777 WO2016062287A1 (zh) 2014-10-24 2015-10-23 山喜多药物在用于制备抑制癌症的医药组合物中的用途
PCT/CN2015/092782 WO2016062291A1 (zh) 2014-10-24 2015-10-23 千忧解药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092677 WO2016062270A1 (zh) 2014-10-24 2015-10-23 呼吸系统疾病用药用于制备抗癌医药组合物的用途
PCT/CN2015/092775 WO2016062285A1 (zh) 2014-10-24 2015-10-23 神经系统疾病用药在制备抗癌医药组合物中的应用
PCT/CN2015/092768 WO2016062281A1 (zh) 2014-10-24 2015-10-23 心血管疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092653 WO2016062267A1 (zh) 2014-10-24 2015-10-23 奈必洛尔在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092666 WO2016062269A1 (zh) 2014-10-24 2015-10-23 阿那格雷在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092714 WO2016062275A1 (zh) 2014-10-24 2015-10-23 阿折地平在制备治疗癌症的医药组合物中的用途
PCT/CN2015/092761 WO2016062279A1 (zh) 2014-10-24 2015-10-23 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途
PCT/CN2015/092779 WO2016062288A1 (zh) 2014-10-24 2015-10-23 代谢性疾病药物用于制备抑制癌症的医药组合物的用途
PCT/CN2015/092617 WO2016062265A1 (zh) 2014-10-24 2015-10-23 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途

Family Applications After (7)

Application Number Title Priority Date Filing Date
PCT/CN2015/092697 WO2016062272A1 (zh) 2014-10-24 2015-10-23 免疫疾病用药物在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092776 WO2016062286A1 (zh) 2014-10-24 2015-10-23 脱克钙药物在用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092753 WO2016062278A1 (zh) 2014-10-24 2015-10-23 内分泌疾病用药在制备抑制癌症的医药组合物中的应用
PCT/CN2015/092780 WO2016062289A1 (zh) 2014-10-24 2015-10-23 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途
PCT/CN2015/092632 WO2016062266A1 (zh) 2014-10-24 2015-10-23 氨氯地平在制备抑制癌症的医药组合物中的用途
PCT/CN2015/092686 WO2016062271A1 (zh) 2014-10-24 2015-10-23 抗生素药物用于制备治疗癌症的医药组合物的用途
PCT/CN2015/092746 WO2016062277A1 (zh) 2014-10-24 2015-10-23 驱虫药用于制备抗癌医药组合物中的应用

Country Status (9)

Country Link
US (7) US20170304388A1 (zh)
EP (3) EP3222278B1 (zh)
JP (1) JP6539345B2 (zh)
KR (1) KR102490334B1 (zh)
CN (3) CN107106523A (zh)
AU (2) AU2015335375B2 (zh)
ES (2) ES2973279T3 (zh)
TW (21) TW201615186A (zh)
WO (21) WO2016062283A1 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
TW201615186A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 脫克鈣藥物應用於癌症治療
AU2015370666B2 (en) 2014-12-22 2020-09-03 Arovella Therapeutics Limited Prevention and treatment of metastatic disease in thrombocytotic cancer patients
WO2017116049A1 (ko) * 2015-12-31 2017-07-06 경북대학교 산학협력단 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (zh) * 2016-06-15 2016-11-09 中南大学湘雅医院 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用
WO2018072135A1 (zh) * 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 二氢吡啶类钙拮抗剂用于治疗癌症的用途
CN108066345A (zh) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 一种具有抗肿瘤作用的化合物
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
US20200179404A1 (en) * 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
WO2019008516A2 (en) * 2017-07-03 2019-01-10 Menri Group Ltd. TREATMENT OF CANCER WITH DIHYDROPYRIDINES
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
KR101933805B1 (ko) 2017-10-17 2018-12-28 성균관대학교산학협력단 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물
CN108186652A (zh) * 2017-12-28 2018-06-22 深圳大学 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用
AU2019214891B2 (en) 2018-01-30 2024-08-01 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
FR3090084B1 (fr) 2018-12-18 2023-10-13 Securengy Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent.
WO2020132253A1 (en) * 2018-12-19 2020-06-25 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
EP3949959A4 (en) * 2019-04-04 2022-05-11 Daegu-Gyeongbuk Medical Innovation Foundation PHARMACEUTICAL COMPOSITION COMPRISING TRIMEBUTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USED AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
WO2020206078A1 (en) * 2019-04-05 2020-10-08 University Of North Texas Health Science Center At Fort Worth Antidepressants for the treatment or prevention of memory loss and/or cognitive decline or dysfunction in aging
CA3136353A1 (en) * 2019-04-11 2020-10-15 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (zh) * 2019-05-31 2019-08-30 天津科技大学 一种噻吨溴类化合物的应用
CN110742890A (zh) * 2019-10-24 2020-02-04 暨南大学 洛美利嗪在制备抗结肠癌药物中的应用
CN110840887A (zh) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 三氯苯达唑在制备治疗乳腺癌的药物中的应用
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN111067899B (zh) * 2020-01-08 2021-03-05 温州医科大学 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (zh) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途
CN111557941A (zh) * 2020-06-15 2020-08-21 浙江大学 Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用
CN111848717A (zh) * 2020-08-07 2020-10-30 四川大学 靶向调控线粒体能量代谢的化合物及其应用和药物
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN112336725A (zh) * 2020-12-11 2021-02-09 吴照球 甲氧苄啶的医药新用途
CN112569342A (zh) * 2020-12-21 2021-03-30 中南大学 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
CN112569215A (zh) * 2020-12-30 2021-03-30 东莞市人民医院 度米芬在制备防治结直肠癌的药物中的应用
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (zh) * 2021-06-28 2022-12-30 四川大学 Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (zh) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 五氟利多在制备治疗子宫内膜癌的药物中的应用
CN115887455B (zh) * 2022-08-04 2024-04-05 北京大学人民医院 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用
CN115778957B (zh) * 2022-11-04 2024-06-21 天津中医药大学 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用
CN116570579A (zh) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用
CN118059099B (zh) * 2024-04-19 2024-06-14 四川大学华西医院 帕罗西汀联合asct2抑制剂用于制备治疗肝癌的药物中的应用及药物组合物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2150942C1 (ru) * 1993-10-01 2000-06-20 Синтекс (Ю.ЭС.ЭЙ.) Инк. Оральные суспензии, содержащие высокие дозы мофетила микофенолята
CZ287513B6 (en) * 1994-12-28 2000-12-13 Janssen Pharmaceutica Nv Nebivolol functioning as anti-atherogenic agent
CA2344057C (en) * 1998-09-15 2008-11-18 Eli Lilly And Company Treatment of persistent pain
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
CN100473644C (zh) * 2000-07-07 2009-04-01 塔夫茨大学信托人 9-取代的二甲胺四环素化合物
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0414568A (pt) * 2003-09-18 2006-11-07 Combinatorx Inc combinações de drogas para o tratamento de neoplasmas
OA13284A (en) * 2003-11-06 2007-01-31 Corporation Celgene Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
JP2007537246A (ja) * 2004-05-12 2007-12-20 バイオランクス カンパニー リミテッド ニコチン酸誘導体を有効成分として含む癌予防及び治療剤
AU2005244988C1 (en) * 2004-05-21 2012-06-28 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
CN1279980C (zh) * 2004-10-14 2006-10-18 孔庆忠 一种抗实体肿瘤药物组合物
JP2006298781A (ja) * 2005-04-15 2006-11-02 Geno Membrane:Kk エストロン３硫酸トランスポーター活性阻害剤
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (zh) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 制备缬沙坦的方法
SI1909778T1 (en) * 2005-07-28 2018-07-31 Academisch Ziekenhuis bij de Universiteit van Amsetrdam MONOFENOLNE, BENZENDIOLE OR SULFHYDRYAL COMPOUNDS FOR THE USE IN THE TREATMENT OF MELANOMS
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CN101099724A (zh) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 一种微粉化来曲唑及其组合物
CN101103976A (zh) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 一种含阿那曲唑的口服药物组合物及其制备工艺
WO2008085875A2 (en) * 2007-01-05 2008-07-17 Cornerstone Therapeutics Inc. R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
JP5358566B2 (ja) * 2007-06-21 2013-12-04 アムジエン・インコーポレーテツド シナカルセトおよびその塩を合成する方法
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (zh) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂
US20090270397A1 (en) * 2008-04-08 2009-10-29 Orlow Seth J Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (zh) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 氨氯地平在制备治疗细胞增生性疾病药物中的用途
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
CN101991553B (zh) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 一种依西美坦片及其制备方法
CN101863806B (zh) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 抗前列腺癌药物(r)-比卡鲁胺的制备方法
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
WO2012015023A1 (ja) * 2010-07-29 2012-02-02 国立大学法人京都大学 抗がん剤のスクリーニング方法
WO2012079232A1 (zh) * 2010-12-15 2012-06-21 Lai Hung-Cheng 用于治疗癌症的化合物及其应用
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
CN102688493B (zh) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN102813643B (zh) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 bumetanide在抑制肝癌细胞转移中的应用
US9757424B2 (en) * 2011-09-27 2017-09-12 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
EP2776129B2 (en) * 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
CN102600077B (zh) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 吉西他滨或其盐纳米乳剂注射液及其制备方法
ES2384069B1 (es) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet y tumores neuroblásticos
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014036654A1 (en) * 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
PT2897620T (pt) * 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
BR112015007144A2 (pt) * 2012-10-04 2017-12-12 Ab Science uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
CN102872066B (zh) * 2012-10-19 2014-07-02 厦门大学 伊维菌素及其衍生物的用途
CA3159085A1 (en) * 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
CN103933569B (zh) * 2013-01-22 2017-01-11 复旦大学 一种抗肺癌药物组合物及其应用、药盒和包装件
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (zh) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 阿那格雷及其衍生物的抗肿瘤用途
CN103396419A (zh) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法
CN103536925B (zh) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 强心苷化合物在非小细胞肺癌治疗中的应用
CN103622975B (zh) * 2013-11-07 2016-06-15 广东药学院 格列吡嗪在制备治疗肿瘤药物中的应用
CN106572988B (zh) * 2014-04-08 2022-04-08 卫理公会医院 Inos抑制性组合物及其作为乳腺癌治疗剂的用途
TW201615186A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 脫克鈣藥物應用於癌症治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHEN WEIDONG ET AL.: "The effects of refecoxib on inhibiting the growth and inducing apoptosis of hepatocellular carcinoma cell lines HepG2 and human normal liver cell line QSG7701", CHINESE JOURNAL OF HEPATOLOGY, vol. 14, no. 11, 30 November 2006 (2006-11-30), pages 863 - 865, XP055274808, ISSN: 1007-3418 *
WEI YAN ET AL.: "Effects of Omeprazole on the Proliferation and Apoptosis of Hepatoma Cell Line HepG2", JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION), vol. 43, no. 4, 31 December 2012 (2012-12-31), pages 513 - 516, ISSN: 1672-173X *

Also Published As

Publication number Publication date
WO2016062265A1 (zh) 2016-04-28
KR102490334B1 (ko) 2023-01-18
TW201615221A (zh) 2016-05-01
TW201615194A (zh) 2016-05-01
WO2016062291A1 (zh) 2016-04-28
TW201615217A (zh) 2016-05-01
ES2954860T3 (es) 2023-11-27
EP3210604C0 (en) 2024-02-14
TW201615192A (zh) 2016-05-01
EP3210604B1 (en) 2024-02-14
TW201615223A (zh) 2016-05-01
TWI652060B (zh) 2019-03-01
TW201615197A (zh) 2016-05-01
US10098852B2 (en) 2018-10-16
CN107106523A (zh) 2017-08-29
JP6539345B2 (ja) 2019-07-03
US20170304387A1 (en) 2017-10-26
WO2016062272A1 (zh) 2016-04-28
US20170304286A1 (en) 2017-10-26
TW201615186A (zh) 2016-05-01
TW201615219A (zh) 2016-05-01
WO2016062269A1 (zh) 2016-04-28
TWI672150B (zh) 2019-09-21
TW201615191A (zh) 2016-05-01
EP3222278C0 (en) 2023-06-14
WO2016062278A1 (zh) 2016-04-28
KR20170084034A (ko) 2017-07-19
WO2016062285A1 (zh) 2016-04-28
TW201615226A (zh) 2016-05-01
WO2016062267A1 (zh) 2016-04-28
TW201615224A (zh) 2016-05-01
AU2015335391A1 (en) 2017-06-01
EP3235497A4 (en) 2018-06-13
EP3222278A4 (en) 2018-06-20
WO2016062266A1 (zh) 2016-04-28
US20170312260A1 (en) 2017-11-02
US20170216247A1 (en) 2017-08-03
TW201615189A (zh) 2016-05-01
WO2016062275A1 (zh) 2016-04-28
WO2016062279A1 (zh) 2016-04-28
WO2016062277A1 (zh) 2016-04-28
TW201615184A (zh) 2016-05-01
WO2016062287A1 (zh) 2016-04-28
EP3222278B1 (en) 2023-06-14
AU2015335375A1 (en) 2017-05-18
AU2015335375B2 (en) 2020-09-10
EP3222278A1 (en) 2017-09-27
TW201615193A (zh) 2016-05-01
US20170304218A1 (en) 2017-10-26
TW201615195A (zh) 2016-05-01
ES2973279T3 (es) 2024-06-19
WO2016062281A1 (zh) 2016-04-28
US20170304388A1 (en) 2017-10-26
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
CN106999470A (zh) 2017-08-01
TW201615222A (zh) 2016-05-01
EP3210604A4 (en) 2018-06-27
TW201615188A (zh) 2016-05-01
AU2015335391B2 (en) 2018-06-21
TW201615220A (zh) 2016-05-01
WO2016062288A1 (zh) 2016-04-28
TWI663969B (zh) 2019-07-01
WO2016062289A1 (zh) 2016-04-28
TW201615196A (zh) 2016-05-01
WO2016062271A1 (zh) 2016-04-28
TWI663984B (zh) 2019-07-01
US10045962B2 (en) 2018-08-14
CN107106550A (zh) 2017-08-29
EP3235497A1 (en) 2017-10-25
WO2016062270A1 (zh) 2016-04-28
TW201615225A (zh) 2016-05-01
JP2017532351A (ja) 2017-11-02
TWI621434B (zh) 2018-04-21
WO2016062286A1 (zh) 2016-04-28
TW201615218A (zh) 2016-05-01
EP3210604A1 (en) 2017-08-30
WO2016062290A1 (zh) 2016-04-28
WO2016062283A1 (zh) 2016-04-28

Similar Documents

Publication Publication Date Title
WO2016062274A1 (zh) 消化系统疾病用药物在制备抑制癌症的医药组合物中的应用
CN106361993B (zh) 一种防治胃黏膜损伤的药物组合物及其制备方法
CN109820954B (zh) 一种中药组合物、制备方法及其在制备治疗慢性非萎缩性胃炎药物上的用途
CN102526640B (zh) 一种泮托拉唑钠药物组合物及其制备工艺
CN101461816B (zh) 柯里拉京的新用途
CN106924539B (zh) 一种治疗消化性溃疡、胃炎及反流性食管炎的中药制剂及其制备方法和应用
CN105535495A (zh) 一种培元固本治疗食管癌的中药组合物及制备方法
CN101036732B (zh) 治疗食道癌的中药制剂及其配制方法
RU2322999C2 (ru) Способ профилактики и лечения осложнений при лучевой и/или химиотерапии рака различной локализации
CN104922312A (zh) 一种治疗恶性肿瘤化疗后便秘的中药组合物
CN104147194A (zh) 一种治疗慢性鼻窦炎的中药组合物
CN106619745A (zh) 治疗胃肠疾病的生物菌液及其制备方法
CN102886016A (zh) 治疗胆囊息肉的中药制剂
CN101693084A (zh) 一种治疗胃脘痛阴虚证的药物组合物及其制备方法
CN105031488A (zh) 一种治疗肠、胃炎的中药组合物
CN104784651B (zh) 一种制备用于治疗胃溃疡的药物制剂的方法
CN108939011A (zh) 一种治疗癌症的中草药配方
CN103285326B (zh) 一种治疗胃肠动力障碍的药物组合物
CN115154576B (zh) 一种治疗恶性肿瘤相关性腹泻的中药组合物
CN106421600A (zh) 一种治疗消化道出血的中西药复方制剂及制备方法
CN106237245B (zh) 一种治疗急慢性腹泻的中药组合物及其制剂和应用
CN107753825A (zh) 一种治疗寒邪客胃型胃病的中药组合物
CN105853399A (zh) 百秋李醇在制备治疗慢性胃炎的药物中的应用
CN104398704A (zh) 一种治疗胃癌的中药组合物及其制备方法
CN103893512A (zh) 一种治疗痛风性关节炎的中药组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15852274

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15852274

Country of ref document: EP

Kind code of ref document: A1